Over three quarters of healthcare professionals call for co-created patient materials to drive engagement and trust, ultimately helping more patients benefit ...

How was a new rare disease discovered through Singapore’s Undiagnosed Disease Program? And how will technology allow us to ...

For a child with a rare disease, a doctor’s continuing education can end a years-long diagnostic odyssey and unlock access to ...

Discover how AI-powered tools are transforming rare disease diagnosis, patient care, and clinical decision-making.

Japanese prosecutors have laid formal charges against Novartis in the clinical data manipulation scandal that has already claimed the jobs of several senior executives. Novartis’ local subsidiary and ...

When influence outpaces expertise However, the rise of health content on social media has also fuelled the parallel problem ...

The NHS has treated the first patient with Zolgensma, Novartis’ spinal muscular atrophy (SMA) gene therapy. Five-month-old Arthur Morgan, who was diagnosed with SMA in May, has received the once-off ...

GSK has announced it is investing over £270m to build a new vaccine manufacturing facility at its Wavre campus in Belgium. The investment follows the launch of the company’s new respiratory syncytial ...

ESMO celebrates 50 years of focusing on oncology research; Improving cardiovascular disease therapy; Global pharma pricing impact on supply chains ...

The US FDA has announced the launch of the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot, designed to promote safe access to digital health devices. The pilot ...

Novartis’ radiogland therapy (RLT) Pluvicto – lutetium Lu 177 vipivotide tetraxetan – has received its first approval in Europe as a treatment for advanced prostate cancer from the Medicines and ...

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab. Biocon Biologics’ Vevzuo has been authorised to prevent bone complications ...